RT Journal Article
T1 Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients".
A1 Rodriguez-Peralvarez, Manuel
A1 Colmenero, Jordi
A1 Salcedo, Magdalena
K1 COVID-19
K1 SARS-CoV-2
K1 Calcineurin inhibitors
K1 Everolimus
K1 Immunosuppression
K1 Mycophenolate
K1 Pneumonia
K1 Tacrolimus
K1 Transplantation
AB We read with great interest the letter by G. J. Webb et al. regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (COVID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors  influencing outcomes. We completely agree with this conclusion, which may also be true for non-transplant patients with COVID19. However, some statements require further clarification.
PB Elsevier
YR 2021
FD 2021-04-03
LK http://hdl.handle.net/10668/17590
UL http://hdl.handle.net/10668/17590
LA en
NO Rodríguez-Perálvarez M, Colmenero J, Salcedo M; Spanish Society of Liver Transplantation (SETH). Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients". J Hepatol. 2021 Jul;75(1):228-229
DS RISalud
RD Apr 12, 2025